News
Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...
Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...
Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 ...
Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...
Novartis hat die Prognose für das Gesamtjahr angehoben, nachdem der Gewinn im ersten Quartal vor allem dank Medikamenten ...
FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...
DPA International on MSN19h
Profit and net sales rise in first quarter for Swiss pharma NovartisSwiss pharmaceutical major Novartis on Tuesday reported higher profit and net sales in the first quarter compared to the same ...
11hon MSN
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results. Amazon listing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback